VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
VERAXA Biotech presented first in vivo proof-of-concept data for its BiTAC-ADC platform at the 17th World ADC Congress, showing significant tumor volume reduction from a single systemically administered 3 mg/kg dose in a xenograft breast cancer model. The data also showed a differentiated safety profile, with no decrease in body weight observed and no effect from non-targeted components, supporting the platform's tumor-restricted activation design.
Key figures
- Drug Name
- BiTAC-ADC
- Phase Of Trial
- Preclinical (xenograft breast cancer model)
- Observed effect
- significant tumor volume reduction, no body-weight decrease
- Single dose mg kg
- 3
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.